Emma has over 20 years combined research experience in cancer biology, oncology drug discovery and translational oncology setting. Most recently, Emma held a R&D leadership position at Pierian Biosciences, a company focused on developing innovative and treatment-directing diagnostic tests to guide personalized cancer medicine and translational science. Prior to Pierian Biosciences, she oversaw and executed biomarker-focused preclinical and early clinical translational studies for targeted oncology programs and successfully managed relationships with global pharmaceutical partners and academic clinical investigators by serving as primary liaison and integrating research and medical affairs role at Prometheus Laboratories, a Nestle Health Science company. Early on in her career, Emma acquired first-hand knowledge of biologics oncology drug discovery and development at Biogen Idec.
Emma received a PhD in Molecular and Cell Biology from the University Louis Pasteur, Strasbourg, France. She trained as a post-doctoral fellow at the Cancer Research UK Institute, University of Cambridge (UK) and Scripps Research Institute, La Jolla, California. She is the inventor and author on numerous patents and peer-reviewed publications.